Damora at Jefferies Global Healthcare Conference: CALR push
On 18 November 2026, Damora (DMRA) utilized the Jefferies Global Healthcare Conference to reveal a targeted approach for its pioneering mutant CALR antibody, DMR-001. The firm acknowledged a substantial unmet need in myeloproliferative neoplasms, yet recognized a competitive landscape with Incyte, which is projected to be two years ahead in development.
Damora explained that its program could differentiate itself through a unique dosing frequency, activity across both major CALR mutation types, and a development strategy built upon insights from prior studies. The company is currently developing DMR-001, a mutant CALR-targeting antibody for essential thrombocythemia and myelofibrosis.
Damora estimated that approximately 45,000 U.S. patients possess mutant CALR mutations, creating an enormous market opportunity exceeding $10 billion. The drug is designed for subcutaneous dosing every four weeks, unlike Incyte's biweekly intravenous approach. Preclinical studies indicate that DMR-001 exhibits activity against both type 1 and type 2 CALR mutations, potentially expanding its reach.
In Australia and the U.S., the company has initiated a Phase I/IB study, drawing on Incyte's published safety data to justify a relatively high starting dose of 100 mg every four weeks. Damora's CEO, Jennifer Jarrett, explained that their antibodies target mutant CALR, a driver mutation present in roughly one-third of patients with myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis.
Damora's market capitalization stands at $1.43 billion, though the biotech firm remains in the cash-burn phase typical of early-stage companies, with a negative EBITDA of $130 million over the past year. The company boasts a robust balance sheet, with liquid assets significantly exceeding short-term obligations and more cash than debt, a crucial safety net for funding clinical trials.
DMR-001 is derived from Fairmount's proprietary Paragon antibody platform, and management highlighted its superior pharmacokinetic profile, particularly its subcutaneous dosing once every four weeks compared to Incyte's biweekly intravenous regimen. Preclinical data suggest that DMR-001 may have better potency against type 2 mutations, which the company views as a significant advantage, as type 2 patients constitute a substantial portion of the market.
Damora emphasized that their approach targets the mutation itself, rather than merely alleviating symptoms, representing a disease-modifying strategy. The company has observed strong physician and patient interest in disease-modifying therapy, leading to an expansion of its Phase I/IB study to Australia and the United States.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.